Mycobacteria multiply in macrophages. Previous work has indicated that inhibition of TGF-beta production will limit the growth of intracellular pathogens including M. avium. This project will examine the potential of TGF-beta antagonists to affect the growth of M. tuberculosis (Mtb) in human macrophages. Studies will include the application of selected antagonists in combination with cytokines and the use of antagonists in vivo to limit infection and disease in mouse models of M. tuberculosis.

Proposed Commercial Applications

Sufficient evidence is available in animals models that TGF-beta antagonists may improve resistance to intracellular organisms. This may prove to be clinically useful and hence has good commercial potential.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI036757-01A1
Application #
2073225
Study Section
Special Emphasis Panel (ZRG5-MBC-2 (04))
Project Start
1995-09-01
Project End
1996-03-31
Budget Start
1995-09-01
Budget End
1996-03-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Corixa Corporation
Department
Type
DUNS #
City
Hamilton
State
WA
Country
United States
Zip Code